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Evaluation of immunomodulatory effects of lamotrigine 
in BALB/c mice
Modulation of the immune system has recently been shown 
to be involved in the pharmacological effects of old anti-
epileptic drugs and in the pathogenesis of epilepsy. There-
fore, the most recent guidelines for immunotoxicological 
evaluation of drugs were consulted to investigate the im-
munomodulatory effects of lamotrigine, a newer antiepi-
leptic drug, in BALB/c mice. These included the in vivo ef-
fects of lamotrigine on delayed-type hypersensitivity 
(DTH) response to sheep red blood cell (SRBC) antigens, 
hemagglutination titer assays and hematological changes. 
In vitro effects of lamotrigine on ConA-induced splenocyte 
proliferation and cytokine secretion were assessed. The re-
sults showed that lamotrigine treatment significantly in-
creased the DTH response to SRBC in the mouse model of 
this study. This was accompanied by a significant increase 
in relative monocyte and neutrophil counts and in spleen 
cellularity. Lamotrigine significantly inhibited ConA-in-
duced splenocyte proliferation in vitro and it significantly 
inhibited IL-2 and TNF-α secretion in ConA-stimulated 
splenocytes. In conclusion, the results demonstrated sig-
nificant immunomodulatory effects of lamotrigine in 
BALB/c mice. These data could expand the understanding 
of lamotrigine-induced adverse reactions and its role in 
modulating the immune system in epilepsy.
Keywords: lamotrigine, epilepsy, cytokine, hypersensitivity, 
immunomodulatory effect, immunotoxicity
Immune system modulation by drugs can result in adverse effects or additional thera-
peutic effects. This alteration might be unintended immunosuppression or immunoen-
hancement. Therefore, the US Food and Drug Administration (FDA) and the International 
Conference on Harmonization (ICH) guidelines for immunotoxicity evaluations of human 
pharmaceuticals recommended immunotoxicity evaluation for drugs in animals to delin-
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eate such potential effects on immune responses (1–3). Antiepileptic drugs are a class of 
drugs with documented immunomodulatory effects, apart from their intended pharma-
cological effects involved in the treatment of epilepsy. On the one hand, these immuno-
modulatory effects have been reflected in a range of immunological/allergic adverse reac-
tions from mild cases of rashes and urticaria to the potentially life threatening reactions 
with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN) and 
Stevens-Johnson syndrome (SJS) (4). On the other hand, more importantly, there is an in-
creasing body of evidence for the potential involvement of the immunomodulatory char-
acteristics of antiepileptic drugs in their therapeutic benefits in the treatment of epilepsy. 
It has recently been shown that modulation of the immune system and inflammation are 
implicated in the pathogenesis of epilepsy (5). This partially involves alteration in cytokine 
secretion, in particular, increased pro-inflammatory cytokines such as IL-1β, IL-6 and 
TNF-a production (6–8). IL-2, in addition, was found to promote seizure generation in 
various murine models of epilepsy (9). Several reports have shown that antiepileptic drugs 
cause alteration in the cellular and humoral immune responses, both in vitro and in vivo. 
In this context, most of the relevant data are focused on only a few classical antiepileptic 
agents, such as carbamazepine, phenytoin and valproate (10–13). However, studies per-
formed on newer antiepileptic drugs, such as lamotrigine, are rare and focused on in vitro 
testing (11–13).
Lamotrigine is a phenyltriazine anticonvulsant that inhibits neuronal voltage-sensi-
tive sodium channels. It is indicated for the management of certain types of epilepsy and 
for bipolar disorder (14). Evaluation of the immunomodulatory effects of lamotrigine has 
become pivotal due to its allergic and hypersensitivity adverse effects. This is also due to 
its effects on the immune system, as described before, in patients with epilepsy where 
these effects could be of therapeutic benefit (14–16). Considering its adverse effects, a 
black box warning was introduced into the monograph of this drug in 2010 owing to the 
serious hypersensitivity adverse effects that have occurred with lamotrigine treatment 
such as SJS, DRESS, and drug-induced hypersensitivity syndrome (14, 15). With regard to 
its immunomodulatory effects in epilepsy, low levels of immunoglobulins have been ob-
served in the sera of epileptic patients treated with lamotrigine (16). In vitro, lamotrigine 
has been shown to inhibit IL-2, IL-1β and TNF-α secretion, but not IL-6 secretion, in 
stimulated-human whole blood (12), while it had no effect on murine splenocyte proli-
feration in vitro (11).
Despite the available data on immunomodulatory effects of lamotrigine, no in vivo 
murine model for the evaluation of the immunomodulatory effects of lamotrigine, based 
on the current pertinent FDA and ICH guidelines (1, 2), is available. Therefore, the aim of 
this work was to characterize the effect of lamotrigine on cellular and humoral immune 
responses in a 21-day in vivo study in BALB/c mice. This included the in vivo evaluation of 
cellular responses (delayed-type hypersensitivity, DTH) and humoral responses (hemag-
glutination titer assay) to a foreign antigen. Other in vivo testing involved the evaluation 
of changes in animal mass, lymphoid organ mass (thymus and spleen), spleen cellularity, 
and total and differential white blood cell (WBC) count. To the best of our knowledge, no 
previous reports have been conducted to assess the effects of lamotrigine on mitogen (con-
canavalin A [ConA])-induced cytokine secretion in isolated splenocytes in vitro. Hence, 
this effect of lamotrigine on immune responses in vitro, along with its effect on splenocyte 
proliferation, was investigated in this study.
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Female BALB/c mice (6 to 8 weeks old, 18–22 g) were obtained from the Applied Sci-
ence University’s animal house, Amman, Jordan. Animals were housed in plastic cages 
with free access to laboratory diet and water. Animals were acclimatized for 1 week in the 
laboratory prior to the experiment. The animals’ room was maintained at ambient tem-
perature of 20–25 °C, relative humidity of 40–70 % and a 12 h light/dark cycle. Ethical ap-
proval of the study protocol was obtained from the Scientific Committee, School of Phar-
macy, The University of Jordan (Amman, Jordan).
Reagents
Lamotrigine powder was purchased from Sana Pharma (Jordan). SRBC suspension, 
RPMI-1640 medium, penicillin-streptomycin solution, fetal bovine serum (FBS), ConA 
(from Canavalia ensiformis) and thiazoyl blue tetrazolium bromide (MTT) were all pur-
chased from Sigma-Aldrich Chemical Co. (USA).
Lamotrigine preparation
For in vivo experiments, a stock solution of lamotrigine in polyethylene glycol (PEG) 
(12.5 mg mL–1) was freshly prepared daily while for in vitro experiments, a stock solution 
of 12 mg mL–1 of lamotrigine was prepared in dimethyl sulfoxide (DMSO) and stored at 
–20 °C.
Dosage and treatment protocol for in vivo experiments 
Mice were randomly divided into five treatment groups of 7 mice each. Mice in the 
control group received 0.2 mL of 20 % PEG in a phosphate buffer saline (PBS) solution in-
traperitoneally (i.p.). The other groups received 0.2 mL of 1.5, 6, 12, or 24 mg kg–1 bm of la-
motrigine i.p. daily for 21 days, corresponding to 0.25-, 1-, 2-, or 4-times the human thera-
peutic dose, resp. Four hours after administration of the last dose, mice were anesthetized 
with diethyl ether inhalation before retro-orbital blood collection for serum preparation 
and WBC count determination. Mice were then sacrificed by cervical dislocation for thy-
mus gland and spleen collection.
Organs and body mass
The mass of each animal was recorded on day 1 and on day 21 (terminal body mass) 
just before dosing. On day 21, four hours after injection, animals were sacrificed and thy-
mus glands and spleens were extracted. Organs were weighed after the removal of con-
nective and adipose tissues. Relative organ masses were calculated as the ratio of organ 
mass (mg) / terminal body mass (g).
Total and differential WBC count
On day 21, before animals were sacrificed, blood was collected from the retro-orbital 
plexus using heparinized capillary tubes. Blood from each mouse was collected into an 
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EDTA tube. The total WBC count was then determined manually under a light micro-
scope. For the differential WBC count, blood films were prepared and stained with poly-
chrome methylene blue-eosin stain (Diamond, Jordan) and then cells were counted under 
the light microscope in a blinded fashion. Three blood films were prepared and examined 
for each mouse.
Single splenocyte cell suspension (SSCS)
For the assessment of spleen cellularity, after treatment with lamotrigine in vivo, the 
spleen from each mouse was individually collected in a sterile Petri dish containing 10 mL 
of RPMI-1640 medium supplemented with 10 % FBS. Spleens were minced between the 
frosted edges of two microscopic slides and the cells were then collected and centrifuged 
at 1200 rpm for 7 min at 4 °C in a refrigerated centrifuge (Sigma, USA). The red blood cells 
(RBC) within the pellets were then lysed using RBC lysis buffer (0.83 % NH4Cl in 100 mmol 
L–1 Tris buffer, pH 7.4) and kept at room temperature (RT) for 3 min. Lysed RBC were then 
removed by washing the cells three times with 10 mL of RPMI-10 % FBS at 1200 rpm for 7 
min at 4 °C. The remaining splenocytes were then suspended in 1 mL of RPMI-10 % FBS 
and the viable splenocyte count was determined using the trypan blue dye exclusion 
method (17).
For in vitro experiments, SSCS was prepared as described above; however, aseptic 
surgical excisions of spleens were performed and sterile tissue culture techniques were 
employed.
Serum antibody titer: hemagglutination log2 titer assay
Seven days before the end of the in vivo experiment (on day 14), mice were intraperito-
neally injected with 5 × 108 SRBC in 0.2 mL of PBS. On day 21, four hours after lamotrigine 
dosing, blood was collected from the retro-orbital plexus into silica gel-containing plain 
tubes (Minicollect®, Greiner, Germany). Blood samples were left to clot at RT for 30 min and 
were then centrifuged at 3000 rpm for 10 min at 4 °C before serum collection. In a round-
bottomed 96-well microtiter plate, serial dilution of the sera in PBS (from 1:2 to 1:2048) was 
conducted. An equal volume of 1 % (V/V) SRBC suspension in PBS was added to 25 µL of 
diluted serum, mixed, covered and incubated at 37 °C for 1 h. The plates were then visu-
ally observed for hemagglutination. Hemagglutination titer was defined as the highest 
dilution of the serum (log2 for the highest dilution) after which the hemagglutination lattice 
structure could not be observed. The method was modified from Fararjeh et al. (17).
DTH response to SRBC
On day 14 of the experiment, the mice were injected subcutaneously with 1 × 109 SRBC 
per 50 µL of PBS. On day 20, the mice were re-challenged with a booster dose of SRBC by 
injecting 1 × 108 SRBC per 10 µL PBS into their right hind foot pad. The left hind foot pad 
of each mouse was injected with an equal volume of PBS as trauma control. Twenty-four 
hours later (day 21), footpads were collected after sacrificing. Right and left footpad vol-
umes were then measured using a digital plethysmometer LE 7500 (Panlab Harvard Ap-
paratus, USA) and the differences between their volumes were calculated (17).
547
Eman Y. Abu-Rish et al.: Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice, Acta Pharm. 67 (2017) 543–555.
 
Cell cultures
SSCS was prepared aseptically as described above. Cultures of splenocytes (2 × 106 
cells mL–1) were suspended in complete RPMI-1640 medium containing 10 % FBS, 2 mmol 
L–1 L-glutamine, 100 U mL–1 penicillin, 100 µg mL–1 streptomycin, 0.05 mmol L–1 2-mercap-
toethanol, 1 mmol L–1 sodium pyruvate and 1× non-essential amino acids (Euroclone, Ita-
ly). Cultures were maintained at 5 % CO2 and 90–95 % humidity at 37 °C. The concentration 
range of lamotrigine (3–24 µg mL–1) was chosen on the basis of therapeutic concentrations 
used in humans and previous studies in mice (11, 12, 18). In addition, a concentration 
higher than the therapeutic range was also tested (48 µg mL–1).
In vitro cellular proliferation assay
Cultures of splenocytes were prepared in flat-bottomed 96-well microplates (4 × 105 
cells per 200 µL per well). Splenocytes were either treated with lamotrigine at final concen-
trations of 3, 6, 12, 24 or 48 µg mL–1 or were left untreated (solvent control) and incubated 
for 1 h. Cultures were then co-treated with 1 µg mL–1 of ConA for 24, 48 or 72 h. Two hours 
prior to the end of each incubation interval, an MTT assay was performed as previously 
described (19). Absorbance was then measured at 570 nm using a microplate reader (Biotek, 
USA). The cell viability percent of the control (viability %) was calculated.
Cytokine secretion by splenocytes in vitro
Cultures of splenocytes were prepared in 24-well plates (2 × 106 cells per mL per well). 
Splenocytes were either left untreated (solvent control) or were treated with lamotrigine at 
final concentrations of 3, 6, 12 or 24 µg mL–1 and incubated for 1 h. Cultures were then co-
treated with 1 µg mL–1 of ConA for 24 h. Culture supernatants were collected and used to 
assess IL-2, IL-6 and TNF-α secretion using a Mouse TNF alpha ELISA Ready-SET-Go!™ 
Kit (eBiosciences, USA) as per manufacturer’s protocols. The final concentration of cyto-
kines is presented as pg mL–1 of culture supernatant.
Statistical analysis
Statistical analysis was performed using one-way ANOVA followed by Dunnett’s 
post-hoc analysis testing using Prism 5 software (GraphPad, USA). Data are presented as 
mean ± standard error of the mean (SEM).
RESULTS AND DISCUSSION
Effects of lamotrigine on immune system parameters in vivo
Assessment of the in vivo effects of drugs on animal body and organ mass, hemato-
logical parameters and on cellular and humoral immune responses is recommended by 
the FDA and ICH guidelines (1–3). Therefore, the effect of lamotrigine on these parameters 
was investigated in this study.
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Body and organ mass. – As shown in Table I, lamotrigine treatment in four doses over 
21 days did not induce any significant changes in animal terminal body mass, relative 
thymus mass or spleen mass compared to the corresponding masses in the control group. 
The observed increase in terminal body mass in comparison with the initial body mass 
indicated a normal growth rate for the animals at the age of 6–8 weeks. This is in line with 
a previous study in humans, which showed that a maintenance treatment with lamotrig-
ine for one year induced no significant change in the subjects’ body masses compared to 
placebo (20).
WBC count and differential. – Treatment of mice with lamotrigine for 21 days was as-
sociated with a significant in vivo increase in total circulating WBC count at 6 and 12 mg 
kg–1 bm doses only compared to the untreated control group (Fig. 1a). Differential WBC 
staining showed that the relative circulating neutrophil count had increased significantly 
at a 24 mg kg–1 bm dose only, while the relative circulating monocyte count had increased 
at both 12 and 24 mg kg–1 bm of lamotrigine (Figs. 1b, c). However, lamotrigine administra-
tion had no effect on the relative lymphocyte count (Fig. 1d). Eosinophil counts were very 
low in all samples and therefore data are not shown.
Spleen cellularity. – In addition to assessment of the lamotrigine effect on spleen mass, 
its effect on spleen cellularity was also assessed. While data (Table I) showed that the net 
spleen mass was not significantly changed by lamotrigine treatment, lamotrigine, how-
ever, induced a significant increase in spleen cellularity over the whole dose range (1.5–24 
mg kg–1 bm) over 21 days compared to the control (Fig. 2). As a lymphoid organ, the spleen 
contains a large reserve of lymphocytes and monocytes (21).
Cellular and humoral immune responses in vivo. – The induction of circulating WBC and 
splenocyte production after treatment with lamotrigine (as described above) suggests that 
the immune function and responses could be altered with lamotrigine treatment. To test 
this, the effects of lamotrigine on the DTH response to an exogenous antigen (SRBC) and 
on antibody production to this antigen (serum antibody titer) were investigated.
An assay of DTH response to antigens was performed to assess the effect of lamotrig-
ine on the cell-mediated immunity. The DTH response is a T-cell and macrophage depen-












(20 % PEG/PBS) 19.00 ± 0.98 24.50 ± 0.82 1.23 ± 0.06 0.37 ± 0.11
1.5 19.86 ± 1.24 24.60 ± 0.51 1.47 ± 0.12 0.44 ± 0.07
6 20.71 ± 1.37 26.17 ± 0.70 1.36 ± 0.13 0.37 ± 0.03
12 20.43 ± 1.27 26.14 ± 0.83 1.27 ± 0.12 0.34 ± 0.05
24 20.43 ± 1.46 26.33 ± 1.09 1.36 ± 0.14 0.33 ± 0.04
a Mean ± SEM (n = 7).
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dent immune response to antigens (22). The antigen used in this study to induce the DTH 
response in mice was SRBC. SRBC was injected subcutaneously to lamotrigine-treated and 
untreated mice, followed by a re-challenged dose in the paw, which resulted in enhanced 
Fig. 1. Effects of lamotrigine on circulating WBC count: a) total, b-d) differential. Female BALB/c mice 
were daily injected with lamotrigine i.p. at 1.5, 6, 12 or 24 mg kg–1 bm or left untreated (20 % PEG/PBS, 
control) for 21 days before retro-orbital blood collection and manual counting of the indicated cells 
under a light microscope (mean ± SEM, n = 7). Significant difference vs. control: *p < 0.05, **p < 0.01).
Fig. 2. Spleen cellularity assessment in female BALB/c mice after daily i.p. injections of lamotrigine 
(1.5, 6, 12 or 24 mg kg–1 bm) or injection of 20 % PEG/PBS (control) for 21 days before spleen extraction. 
Manual counting of splenocytes in SSCS was performed under a light microscope (mean ± SEM, n = 
7). Significant difference vs. control: *p < 0.05.
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recruitment of cellular infiltrate to the paw (as described in the methods). The results of 
this study showed that the DTH response to SRBC was significantly induced by lamotrig-
ine at the four doses tested compared to the control group (Fig. 3a). This was expressed as 
the difference in paw volume between SRBC-injected and PBS-injected paws. Based on 
ICH guidelines, enhancement of the immune response can exaggerate hypersensitivity 
reactions (2). In this context, previous case reports described DTH reaction after treatment 
with lamotrigine as cases of lamotrigine-induced DRESS (15), where DRESS was defined 
as a type of cell-mediated immune stimulation (DTH reaction) (23). Therefore, the results 
of the current study support the notion that lamotrigine can enhance cellular immune 
responses and can exaggerate DTH reactions.
The effect of lamotrigine on humoral immunity and antibody production in response 
to antigenic stimulation was assessed using the hemagglutination titer assay (22). La-
motrigine-treated and untreated mice were injected with SRBC. Anti-SRBC antibody titers 
were determined in the sera (as described in the methods). The results of this study showed 
that lamotrigine, in the four doses tested, had no effect on the concentration of the anti-
SRBC antibody (expressed as antibody titer) and thus had no effect on B-cell-mediated 
antibody production to SRBC (Fig. 3b).
Immune function responses in vitro. – The mitogen-induced splenocyte stimulation as-
say was used to test the in vitro immune functions of lamotrigine. This in vitro assay is 
considered similar to the in vivo DTH assay regarding the assessment of immune cell re-
sponse to antigens (22). Therefore, the effect of lamotrigine on the inflammatory responses 
of splenocytes treated with a mitogen (ConA) in vitro was tested. This included splenocyte 
proliferation response using the MTT assay and cytokine secretion response using ELISA.
ConA-induced splenocyte proliferation in vitro. – ConA-induced splenocyte proliferation 
was significantly inhibited following the treatment with lamotrigine in the whole concen-
tration range 12–48 µg mL–1 after 48 and 72 h of incubation but not after 24 h (Fig. 4). How-
ever, Basta-Kaim et al. (11) showed that lamotrigine had no effect on ConA-induced sple-
nocyte proliferation in vitro after 72 h of incubation. The difference between these results 
and the results of the current study could be ascribed to the difference in experimental 
Fig. 3. Lamotrigine-enhanced murine delayed-hypersensitivity response to SRBC in female BALB/c 
mice daily injected with lamotrigine i.p. at 1.5, 6, 12 or 24 mg kg–1 bm or left untreated (20 % PEG/PBS, 
control) for 21 days. a) DTH assay, b) hemagglutination titer assay (log2 of the highest dilution was 
used as the antibody titer (mean ± SEM, n = 7). Significant difference vs. control: *p < 0.05.
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conditions, such as isolating splenocytes from male C57BL/6 mice of about 3 months of age, 
while in this study female BALB/c mice of 1.5–2 months of age were used. In this regard, 
strain- and sex-associated differences in the regulation of immune responses in mice have 
been reported previously (24, 25). In addition, in contrast to the results of this study, Nais-
bitt et al. (26) demonstrated that lamotrigine enhanced the proliferation of peripheral blood 
mononuclear cells (PBMC) isolated in vitro from patients with lamotrigine-hypersensitiv-
ity. This discrepancy could be attributed to the use of human white blood cells, isolated 
from patients with epilepsy in the report of Naisbitt et al., whereas the current study dem-
onstrated effects of lamotrigine on murine splenocytes isolated from mice without epi-
lepsy. In this regard, several immunological changes have been previously reported to be 
involved in the pathogenesis of epilepsy that cannot be separated from those of antiepi-
leptic drugs (27).
Cytokine secretion in ConA-stimulated splenocytes in vitro. – The effect of lamotrigine on 
cytokine secretion by ConA-stimulated splenocytes in vitro was studied after 24 h of incu-
bation as lamotrigine had no effect on cell viability at this time point. Lamotrigine treat-
ment of ConA-treated splenocytes resulted in a dose-dependent inhibition of TNF-α and 
IL-2 secretion, in particular, following the treatment with 12 and 24 µg mL–1. However, 
lamotrigine treatment for 24 h had no effect on IL-6 secretion in ConA-treated splenocytes 
in vitro in the concentration range tested (Figs. 5a-c). These results explain the reduction in 
ConA-induced splenocyte proliferation presented in this study. ConA has been long used 
to activate and induce the proliferation of T-lymphocyte population within murine sple-
nocytes (28). T-lymphocyte population accounts for about 40–50 % of immune cells within 
the murine spleen (29). Once activated, T-lymphocytes secrete IL-2, which is considered to 
be the main growth factor that stimulates T-lymphocyte proliferation (30). Therefore, the 
reduction in splenocyte proliferation by lamotrigine could be attributed to the inhibitory 
effect of lamotrigine on ConA-induced IL-2 production. As regards TNF-alpha, it is main-
ly produced by monocytes; in addition, it is secreted by activated T-lymphocytes (30). 
Therefore, the reduction in TNF-α production could be partially attributed also to the in-
Fig. 4. Lamotrigine inhibited the proliferation of ConA-stimulated splenocytes in vitro. Cultures of 
isolated splenocytes were treated with lamotrigine at concentrations of 3, 6, 12, 24 and 48 µg mL–1, or 
were left untreated (control) for 1 h before being stimulated with ConA (1 µg mL–1) for 24, 48 or 72 h. 
Cellular proliferation was measured using MTT assay (mean ± SEM, n = 4, each experiment in tripli-
cate). Significant difference vs. control: *p < 0.05, **p < 0.01, ***p < 0.001.
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hibitory effect of lamotrigine on ConA-induced T-cell activation. IL-6 is a T-helper 2 cyto-
kine mainly produced by T-cells and macrophages (30). The results of this study showed 
that lamotrigine had no effect on ConA-induced IL-6 production by murine splenocytes. 
This might be attributed to a possible difference in the effect of lamotrigine on the produc-
tion of cytokines by the different subsets of T-cells, where IL-2 is a T-helper 1 cytokine 
while IL-6 is a T-helper 2 cytokine (30).
Compared to previous reports, similar effects of lamotrigine on the three cytokines 
have been found after stimulation of whole blood obtained from healthy donors, with 
toxic shock syndrome toxin-1 (TSST-1) (12). However, another study showed that lamotrig-
ine inhibited IL-2 and IL-6 secretion but not TNF-α secretion in human whole blood after 
stimulation with a combination of anti-CD3 and anti-CD40 antibodies (12). Therefore, the 
use of different stimulants could result in different immunomodulatory effects of la-
motrigine. Regarding epilepsy, inhibition of IL-2 and TNF-α production might be benefi-
cial in the management of epilepsy as these cytokines were found to be involved in the 
pathogenesis of epilepsy (6, 7).
In vivo results of the current study demonstrated enhancement of several parameters 
within the immune system after lamotrigine treatment. The in vitro results, though, demon-
strated that lamotrigine inhibited ConA-induced splenocyte proliferation and IL-2 and 
Fig. 5. Effects of lamotrigine on TNF-α, IL-2 and IL-6 secretion in ConA-stimulated splenocytes in 
vitro. Cultures of isolated splenocytes were treated with lamotrigine at concentrations, of 3, 6, 12, 24 
and 48 µg mL–1 or were left untreated (control) for 1 h before being stimulated with ConA (1 µg mL–1) 
for 24 h. Culture supernatants were used to assess: a) TNF-α levels, b) IL-2 levels, c) IL-6 levels, using 
ELISA (mean ± SEM, n = 4). Significant differences vs. control: *p < 0.05, **p < 0.01.
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TNF-α secretion. In comparison with other antiepileptic drugs, the majority of classical 
antiepileptic drugs exert immunosuppressive properties; however, many of them can still 
enhance the immune system (4). Clinical studies revealed that several immunological pa-
rameters and the levels of several immunoglobulins were depressed in patients treated 
with carbamazepine or phenytoin (10). However, carbamazepine and phenytoin resulted 
in elevated blood levels of IL-2 and IL-1 in patients with epilepsy, respectively, while val-
proic acid resulted in increased IL-1, IL-6 and IL-5 blood levels (4, 8). In contrast to in vivo 
studies, carbamazepine, phenytoin and valproic acid inhibited IL-2, IL-4, IL-6 and TNF-α 
secretion in vitro (4, 11–13). Thus, reports on the effects of antiepileptic drugs on the im-
mune system are commonly inconsistent or conflicting because of different experimental 
conditions in the different studies and because the effects of the drugs cannot be separated 
from those of seizures (27). In addition, different types of epilepsy are characterized by 
different patterns of immunological alteration (31). Consequently, the results of this study 
emphasize the immunomodulatory effects of antiepileptic drugs, particularly lamotrigine, 
which could be enhancement or inhibition of the immune system depending on the ex-
perimental conditions. This explains the fact that lamotrigine might result in hypersensi-
tivity reactions as a case of immune system stimulation while it can still exert beneficial 
effects in modulating the inflammatory state in patients with epilepsy.
CONCLUSIONS
Findings of the present study demonstrated that lamotrigine had significant immu-
nomodulatory properties in mice, both in vivo and in vitro. This was shown in enhancement 
of relative monocyte and neutrophil counts, increased spleen cellularity, and enhanced 
cellular adaptive immune response in vivo, as shown in the enhanced DTH response to 
SRBC. Lamotrigine, in addition, resulted in a significant suppression of ConA-induced 
splenocyte proliferation and IL-2 and TNF-α secretion in vitro. These results provide in-
sights into possible effects implicated in lamotrigine-induced immunological adverse ef-
fects and possibly further clarify its role in modulating the immune system in epilepsy. 
Therefore, the development of immunological adverse effects, and seizure control, should 
be carefully monitored during lamotrigine treatment. Further studies, however, are neces-
sary to investigate the detailed mechanisms behind the immunomodulatory effects of la-
motrigine and to investigate these effects during chronic exposure protocols.
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